Cargando...
CD19 CAR T Cells Expressing IL-12 Eradicate Lymphoma in Fully Lymphoreplete Mice through Induction of Host Immunity
Chimeric antigen receptor (CAR) T cell therapy represents a significant advancement in cancer therapy. Larger studies have shown ∼90% complete remission rates against chemoresistant and/or refractory CD19(+) leukemia or lymphoma. Effective CAR T cell therapy is highly dependent on lymphodepleting pr...
Gardado en:
| Publicado en: | Mol Ther Oncolytics |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
American Society of Gene & Cell Therapy
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5772011/ https://ncbi.nlm.nih.gov/pubmed/29367945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2017.12.003 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|